Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2672619 | 0.90 | MMP8 (0.54) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL25403051 | 0.87 | MMP8 (0.55) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL901841 | 0.87 | EPHX2 (0.49) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL15274695 | 0.87 | EPHX2 (0.49) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL901733 | 0.86 | EPHX2 (0.50) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL534123 | 0.84 | MMP8 (0.52) | MMP8MAPTLMNANPSR1ALDH1A1 | |
| SCHEMBL3784871 | 0.84 | PPARG (0.49) | EPHX2MMP8PPARGMAPTLMNA | |
| SCHEMBL2428822 | 0.84 | SMN1; SMN2 (0.52) | MMP8MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL15262431 | 0.83 | TSHR (0.42) | MMP8MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL534859 | 0.83 | ALDH1A1 (0.48) | EPHX2MMP8PPARAPPARGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| CN-103328479-A | 7-hydroxy-pyrazolo [1,5-a ] pyrimidine compounds and their use as CCR2 receptor antagonists | PROXIMAGEN LTD | 2013-09-25 | — | — | CN | disclosed |
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2129661-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | Argenta Oral Therapeutics Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2008119917-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | NR1H2, GPR52, HRH2 | EPHX2 1648/4885MMP8 2193/4885PPARA 624/4885 |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | EPHX2 1169/4885MMP8 992/4885PPARA 718/4885 |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | EPHX2 849/4885MMP8 1240/4885PPARA 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.